Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients

Recruiting now · Not applicable

Conditions studied: Elderly, Prostate Cancer

In brief

This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.

Key facts

Study ID

NCT06824818

Run by

University of Chicago

People needed

155

Starts

2026-06-01

Expected to finish

2027-06-01

Last updated by the study team

2025-10-01

Who can join

Age: 70 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Prostate cancer with >3 years of LHRH agonist therapy.
• Age ≥70 years.
• ECOG performance status ≤2
• Baseline testosterone of < 20 ng/ml
• No prior chemotherapy or Lu-PSMA (unless survival predictions are favorable).
• Ability to understand and sign informed consent.

You may not qualify if…

• none

Where it is running

• The University of Illinois at Chicago (UIC) — Chicago, Illinois, United States (enrolling)
• UChicago Medicine Comprehensive Cancer Center — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.